SLC5A2 and type 2 diabetes mellitus: The large increase in dual combination therapy may also be related to the more widespread use of SGLT-2 inhibitors and GLP-1 receptor agonists, as these agents demonstrated benefits on cardiovascular and renal endpoints in patients with T2DM [50,51].